Dr. David Eifrig's Prosperity Investor — Product Intel

What It Is

• A premium healthcare-sector research newsletter from Stansberry Research, edited by Dr. David Eifrig with co-editors Thomas Carroll and John Engel.
• Includes a model portfolio, regular research updates, and special reports; dual mandate of financial gains plus healthcare navigation guidance.

Core Mechanism / Strategy

• Built on the "Health Care Singularity" thesis: AI + digitized health data (records, genomics, imaging, drug databases) collapsing the gap between medical discovery and clinical practice.
• Two-track investment approach: (1) defensive "forever stocks" for compounding, (2) speculative innovators for high upside.
• Additional angles: biotech buyout/acquisition arbitrage, healthcare as an inflation/recession hedge, options income (via Eifrig's other services).

What the Subscriber Gets

• Report 1: 7 "Forever" Health Stocks to Potentially Double the Market, Every Year
• Report 2: The No. 1 Opportunity of My Life: 3 Chances at 1,000%-Plus Gains in the Health Care Singularity
• Report 3: 5 Ways to Grow Your Healthspan, Starting Now
• Bonus book: The Living Cure (2nd edition, digital)
• Future coverage teased: cannabis and psychedelics investing.

Differentiators / Positioning

• Fuses wealth-building with personal-health navigation ("save your life AND make you rich").
• Three-expert "dream team" (physician/MBA/former Goldman + two credentialed healthcare analysts).
• Novel "Health Care Singularity" big-idea framing.

Target Audience

• Investors over 40 / retirement-focused, health-conscious, frustrated with the healthcare system.
• Existing Stansberry subscribers; conservative but willing to hold long-term.

Offer Structure

• List price $5,000/year; charter-member price $2,000 for two years (framed as 80% off).
• Charter membership positioned as one-time, expiring "in days."
• Guarantee: badge shown in imagery but not explained in copy.

Last enriched by FID from 1 promo(s).

Parent Company: Stansberry Research

• A premium healthcare-sector research newsletter from Stansberry Research, edited by Dr. David Eifrig with co-editors Thomas Carroll and John Engel.
• Includes a model portfolio, regular research updates, and special reports; dual mandate of financial gains plus healthcare navigation guidance.

• Built on the "Health Care Singularity" thesis: AI + digitized health data (records, genomics, imaging, drug databases) collapsing the gap between medical discovery and clinical practice.
• Two-track investment approach: (1) defensive "forever stocks" for compounding, (2) speculative innovators for high upside.
• Additional angles: biotech buyout/acquisition arbitrage, healthcare as an inflation/recession hedge, options income (via Eifrig's other services).

• Report 1: 7 "Forever" Health Stocks to Potentially Double the Market, Every Year
• Report 2: The No. 1 Opportunity of My Life: 3 Chances at 1,000%-Plus Gains in the Health Care Singularity
• Report 3: 5 Ways to Grow Your Healthspan, Starting Now
• Bonus book: The Living Cure (2nd edition, digital)
• Future coverage teased: cannabis and psychedelics investing.

• Fuses wealth-building with personal-health navigation ("save your life AND make you rich").
• Three-expert "dream team" (physician/MBA/former Goldman + two credentialed healthcare analysts).
• Novel "Health Care Singularity" big-idea framing.

• Investors over 40 / retirement-focused, health-conscious, frustrated with the healthcare system.
• Existing Stansberry subscribers; conservative but willing to hold long-term.

• List price $5,000/year; charter-member price $2,000 for two years (framed as 80% off).
• Charter membership positioned as one-time, expiring "in days."
• Guarantee: badge shown in imagery but not explained in copy.

Last enriched by FID from 1 promo(s).

• 2026-07-04 — Auto-seeded by FID from promo activity.